EVO vs NBTX
Evotec SE and Nanobiotix S.a., side by side — 6 fiscal years reported in EUR, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | EVO | NBTX |
|---|---|---|
| Revenue | €797.0M | €32.6M |
| Net income | €-196.1M | €-24.0M |
| Gross margin | 14.4% | — |
| Net margin | −24.6% | −73.5% |
| Return on equity | −18.9% | — |
| Diluted EPS | −€1.11 | −€0.50 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | €-99.2M | €-34.0M |
| Equity | €952.5M | — |
| Net debt / equity | −0.02× | — |
| Current ratio | 1.98× | 1.09× |
| Revenue CAGR 5y | 12.3% | 67.0% |
| Profit CAGR 5y | — | — |
EVO bills 24.5× the revenue of NBTX, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
6 years side by side
| Fiscal year | EVO | NBTX |
|---|---|---|
| FY2024 | €797.0M | €-7.2M |
| FY2023 | €781.4M | €36.2M |
| FY2022 | €751.4M | €4.8M |
| FY2021 | €618.0M | €2.6M |
| FY2020 | €500.9M | €2.5M |
| FY2019 | €446.4M | €2.5M |
Net income by year
Bottom line
| Fiscal year | EVO | NBTX |
|---|---|---|
| FY2024 | €-196.1M | €-68.1M |
| FY2023 | €-83.9M | €-39.7M |
| FY2022 | €-175.7M | €-57.0M |
| FY2021 | €215.5M | €-47.1M |
| FY2020 | €6.3M | €-33.6M |
| FY2019 | €38.2M | €-50.9M |
Advertisement
AdSense · Rectangle 336×280